Breaking News Instant updates and real-time market news.

EDIT

Editas Medicine

$33.59

-0.33 (-0.97%)

09:33
01/08/18
01/08
09:33
01/08/18
09:33

Editas Medicine slides after issuing five-year goals at JPMorgan conference

Editas Medicine President and CEO Katrine Bosley will discuss "EM22," the company's long-range goals for the year 2022 In a presentation to investors on Wednesday, January 10, at the 36th Annual J.P. Morgan Healthcare Conference, the company noted earlier. As part of EM22, by year-end 2022 Editas Medicine is driving to deliver on the company's commitment to make medicines for people with serious diseases around the world by advancing: Three experimental medicines in early-stage clinical trials; Two experimental medicines in or ready for late-stage clinical trials; A best-in-class platform and pipeline for developing genomic medicines; and all of these achievements fueled by the company's unique culture. In early trading following the update, Editas shares are down $3.47, or 10.33%, to $30.12.

  • 08

    Jan

  • 26

    Feb

EDIT Editas Medicine
$33.59

-0.33 (-0.97%)

07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Crispr Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Crispr Therapeutics (CRSP) with a Perform rating saying the company is in a weaker patent position than competitor Editas Medicine (EDIT).
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Editas Medicine initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Editas Medicine (EDIT) with a Perform rating saying that while the company currently has the strongest patent position among its CRISPR-based peers, the shares are fairly valued.
09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Editas Medicine initiated with an Overweight at Barclays
Barclays initiated Editas Medicine with an Overweight rating and a $28 price target, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.

TODAY'S FREE FLY STORIES

CEMI

Chembio Diagnostics

$8.70

-0.1 (-1.14%)

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Hot Stocks
Chembio Diagnostics to commercialize disease tests in Brazil »

Chembio Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

FHB

First Hawaiian

$28.94

0.07 (0.24%)

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Conference/Events
First Hawaiian management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

08:02
05/24/18
05/24
08:02
05/24/18
08:02
Conference/Events
Jefferies to hold a conference »

Automotive Aftermarket…

08:02
05/24/18
05/24
08:02
05/24/18
08:02
Conference/Events
Morgan Stanley to hold a symposium »

2nd Annual Small &…

MYO

Myomo

$3.28

-0.02 (-0.61%)

08:02
05/24/18
05/24
08:02
05/24/18
08:02
Hot Stocks
Myomo announces MyoPro availability in 16 new U.S. locations »

Myomo announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$29.22

-0.56 (-1.88%)

08:01
05/24/18
05/24
08:01
05/24/18
08:01
Initiation
Skyline initiated  »

Skyline initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$31.79

-0.08 (-0.25%)

08:01
05/24/18
05/24
08:01
05/24/18
08:01
Conference/Events
Detroit Economic Club to hold a luncheon »

Tony James, Executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 30

    May

WHR

Whirlpool

$164.63

0.3 (0.18%)

08:01
05/24/18
05/24
08:01
05/24/18
08:01
Hot Stocks
Whirlpool announces preliminary results of modified Dutch auction tender offer »

Whirlpool Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

HFC

HollyFrontier

$73.67

0.75 (1.03%)

08:00
05/24/18
05/24
08:00
05/24/18
08:00
Recommendations
HollyFrontier analyst commentary  »

HollyFrontier price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$36.72

0.35 (0.96%)

08:00
05/24/18
05/24
08:00
05/24/18
08:00
Options
JD.com call buyer realizes 1% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNP

Union Pacific

$144.26

1.36 (0.95%)

07:59
05/24/18
05/24
07:59
05/24/18
07:59
Initiation
Union Pacific initiated  »

Union Pacific resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

NCR

NCR Corp.

$30.75

-0.4 (-1.28%)

07:58
05/24/18
05/24
07:58
05/24/18
07:58
Recommendations
NCR Corp. analyst commentary  »

NCR Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:55
05/24/18
05/24
07:55
05/24/18
07:55
Conference/Events
Federal Reserve Bank of Philadelphia President speaks at a conference »

Philadelphia Federal…

MCRB

Seres Therapeutics

$8.12

0.16 (2.01%)

07:55
05/24/18
05/24
07:55
05/24/18
07:55
Conference/Events
Seres Therapeutics to hold a research and development day »

Microbiome Research &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 02

    Jun

OKTA

Okta

$49.49

0.99 (2.04%)

07:52
05/24/18
05/24
07:52
05/24/18
07:52
Recommendations
Okta analyst commentary  »

Okta price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 06

    Jun

  • 12

    Jun

INTU

Intuit

$196.15

5.74 (3.01%)

07:51
05/24/18
05/24
07:51
05/24/18
07:51
Recommendations
Intuit analyst commentary  »

Intuit price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

CIT

CIT Group

$55.27

-0.06 (-0.11%)

07:51
05/24/18
05/24
07:51
05/24/18
07:51
Hot Stocks
CIT Group announces preliminary results of cash tender offer for common stock »

CIT Group announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDU

New Oriental Education

$101.38

4.82 (4.99%)

07:50
05/24/18
05/24
07:50
05/24/18
07:50
Downgrade
New Oriental Education rating change  »

New Oriental Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

TAL

TAL Education

$43.74

1.11 (2.60%)

07:50
05/24/18
05/24
07:50
05/24/18
07:50
Upgrade
TAL Education rating change  »

TAL Education upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:48
05/24/18
05/24
07:48
05/24/18
07:48
Conference/Events
Federal Reserve Bank of Atlanta president delivers opening remarks at conference »

Atlanta Federal Reserve…

DRI

Darden

$85.72

-0.23 (-0.27%)

07:47
05/24/18
05/24
07:47
05/24/18
07:47
Recommendations
Darden analyst commentary  »

Darden added to Top Picks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

PBR

Petrobras

$15.10

-0.6 (-3.82%)

07:46
05/24/18
05/24
07:46
05/24/18
07:46
Downgrade
Petrobras rating change  »

Petrobras downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$15.10

-0.6 (-3.82%)

07:46
05/24/18
05/24
07:46
05/24/18
07:46
Technical Analysis
Technical Take: Petrobras falls on diesel price cuts, regulator scrutiny »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPO

Precipio

$0.50

0.0143 (2.94%)

07:44
05/24/18
05/24
07:44
05/24/18
07:44
Hot Stocks
Precipio receives first order for liquid biopsy DNA enrichment sales in Europe »

Precipio entered into an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QURE

uniQure

$32.87

0.56 (1.73%)

07:44
05/24/18
05/24
07:44
05/24/18
07:44
Initiation
uniQure initiated  »

uniQure initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.